| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | Vinblastine | GDSC1000 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.02 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | -0.38 | 0.02 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.071 | 0.02 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.072 | 0.02 |